Voyager Therapeutics has exercised commercial options for the use of Regenxbio’s NAV ® vectors to develop and commercialize gene therapies for specific neurological diseases, the companies said today.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback